Cell Source, Inc. is a biotechnology company, which focuses on developing cell therapy treatments based on the management of immune tolerance. The company is headquartered in New York City, New York. The company went IPO on 2014-01-14. The firm is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The firm's wholly owned subsidiary is Cell Source Limited (CSL).
Follow-Up Questions
¿Cuál es el ratio P/E de Cell Source Inc (CLCS)?
El ratio P/E de Cell Source Inc es N/A
¿Quién es el CEO de Cell Source Inc?
Mr. Itamar Shimrat es el Chief Executive Officer de Cell Source Inc, se unió a la empresa desde 2014.
¿Qué tal es el rendimiento del precio de la acción CLCS?
El precio actual de CLCS es de 0.44, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Cell Source Inc?
Cell Source Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Cell Source Inc?
La capitalización bursátil actual de Cell Source Inc es $17.6
¿Es Cell Source Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 0 analistas han realizado calificaciones de análisis para Cell Source Inc, incluyendo 0 fuerte compra, 0 compra, 0 mantener, 0 venta, y 0 fuerte venta
